SES Selects Arianespace to Launch EAGLE-1 Satellite for Europe’s Quantum Cryptography
9.11.2022 10:50:00 EET | Business Wire | Press release
The EAGLE-1 satellite, which will support the end-to-end secure Quantum Key Distribution (QKD) system for Europe, will be launched for SES by Arianespace on a Vega C rocket from French Guiana as early as Q4 2024. The satellite will be placed into Low Earth Orbit (LEO). The EAGLE-1 project comprising satellite and ground infrastructure, is developed by SES and its consortium of 20 European partners, with the European Space Agency (ESA) and the European Commission support.
Under the recently-signed agreement with ESA, SES and its partners will design, develop, launch and operate a satellite-based end-to-end QKD system for the purpose of testing and validating space-based secure transmission of cryptographic keys. The first European sovereign space-based QKD system will include the dedicated low earth orbit (LEO) EAGLE-1 satellite and state-of-the-art QKD operations centre in Luxembourg. In the scope of EuroQCI, the EAGLE-1 satellite will enable early access, validation, and integration of space-based QKD for EU Member States.
“Building the EAGLE-1 end-to-end system for secure data transmission and validating the long-distance Quantum Key Distribution technology is an innovative project that will benefit the EU Member States,” said Ruy Pinto, Chief Technology Officer at SES. “We have been working with Arianespace for decades to deliver our satellites into space and are delighted for them to be onboard to launch the EAGLE-1 satellite into orbit.”
“We are delighted and honored by this renewed mark of confidence from the leading global content connectivity service provider SES,” noted Marino Fragnito, Director of Arianespace’s Vega business unit. “Over the last 38 years, Arianespace has carried out 42 launches for its longstanding partner, and Vega C will now continue this successful track record. It is a great honor for us to support our customer’s ambitions and to be part of this mission that aims at implementing Europe’s satellite-enabled cybersecurity technology.”
Following the launch, the EAGLE-1 satellite will complete three years of in-orbit mission supported by the European Commission. During this operational phase, the satellite will allow European Union governments and institutions, as well as critical business sectors, early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.
The EAGLE-1 project is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.
Vega C, the new European light launcher successfully passed its inaugural flight on July 13 and now enters its operational phase under the responsibility of Arianespace. With this contract, Vega C backlog includes over 40 satellites contracts.
Vega C development program has been managed by ESA with 12 Member States of the Agency. Avio Spa (Colleferro, Italy) is the industrial prime of the Vega launch system. Vega C has been upgraded with more powerful first and second stage Solid Rocket Motors and with a larger fairing, which significantly increases payload mass and double allowable volume as compared to Vega. The launcher also better meets the specific needs of small spacecrafts, thanks to its improved SSMS dispenser and to its AVUM+ that allows seven re-ignitions instead of five. Vega C can thus deliver to three different separation orbits for its multiple payloads within the same mission, instead of the two previously possible with Vega.
For more information, visit the EAGLE-1 Newsroom
Follow SES on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Follow Arianespace on:
Twitter | YouTube | LinkedIn | Instagram
About ESA
The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see www.esa.int
The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners. For more information, please visit our website: https://artes.esa.int/
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
About Arianespace
Arianespace uses Space to make life better on Earth by providing launch services for all types of satellites into all orbits. It has orbited over 1,100 satellites since 1980. Arianespace is responsible for operating the new-generation Ariane 6 and Vega C launchers, developed by ESA, with respectively ArianeGroup and Avio as industrial primes. Arianespace is headquartered in Evry, near Paris, and has a technical facility at the Guiana Space Center in French Guiana, plus local offices in Washington, D.C., Tokyo and Singapore. Arianespace is a subsidiary of ArianeGroup, which holds 74% of its share capital, with the balance held by 15 other shareholders from the Ariane and Vega European launcher industry, and ESA and Cnes as censors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006349/en/
Contact information
For further information:
Suzanne Ong
External Communications, SES
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital
Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 10:30:00 EEST | Press release
Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities across traditional and alternative property types throughout Europe.” In h
LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 09:16:00 EEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include: LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into delivery workflows across AI-led software engineering, application modernization, agent orchestration, Si
Sofinnova Partners Appoints David Evans as Partner13.7.2026 09:00:00 EEST | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-sciences investing. Evans’s breadth of experience, anchored in hands-on pharma expertise, contributes complementary expertise to Sofinnova's Crossover Strategy. Evans will play a key role in the Strategy’s late-stage private and public life-sciences investments. His combination of clinical, scientific, and investment expertise strengthens the firm's ability to evaluat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
